Epitranscriptomic control of cancer immunity and therapy resistance

表观转录组调控癌症免疫和治疗耐药性

阅读:1

Abstract

Epitranscriptomics, the study of dynamic chemical modifications on RNA mediated by "writers," "erasers," and "readers," has emerged as a pivotal discipline in elucidating the intricate interplay between cancer and immune regulation. These reversible modifications (e.g. m(6)A, m(5)C, Ψ) govern RNA metabolism, stability, and translation, thereby exerting spatiotemporal control over immune cell differentiation, activation, and function. Dysregulation of RNA-modifying proteins disrupts immune surveillance, enhances tumor cell survival under stress, and promotes chemoradiotherapy resistance by altering RNA splicing, translation, and stress adaptation pathways. This review summarized the recent progress in the regulatory mechanisms profoundly influencing the tumor microenvironment (TME), modulating immune checkpoints, antigen presentation pathways, and the activity of immune cells. Furthermore, we discussed the therapeutic strategies and challenges in targeting epitranscriptomic regulators and epitranscriptomic editing technologies to enhance anti-tumor immune responses and overcome therapeutic resistance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。